Nov 16 (Reuters) – Seawolf Therapeutics on Monday launched publicly with $100 million in funding and a deal with French drugmaker Sanofi worth up to $1.2 billion, as it seeks to develop DNA-based medicines.
• The Series A financing was backed by Versant Ventures, MPM BioImpact and Novartis Venture Fund, with participation from Eli Lilly, CRISPR Therapeutics and others
• San Diego-based Seawolf and Sanofi will develop treatments for bleeding disorders and other undisclosed conditions
• Seawolf could get milestone payments and royalties
• CEO Elizabeth Alcamo told Reuters the agreement includes an upfront payment, though she declined to say how much
• Seawolf’s technology, called TRIDENT, uses tiny fat particles to carry DNA into the nucleus of cells without using viruses
• The company says it can offer longer-lasting effects than RNA medicines and the option of repeat dosing that virus-based gene therapies lack
• The lead program, which has been tested only in animals, aims to build muscle and reduce fat, and could be used for obesity, muscle loss and osteoporosis
• Seawolf expects to pick a drug candidate by late 2027 and file to begin human trials by the end of 2028
• But “we’ll probably need to raise some additional capital” to reach that stage, Alcamo said
(Reporting by Kamal Choudhury in Bengaluru; Editing by Sahal Muhammed)

